.

BioPharmaceutical Business Intelligence

  • Identify first generic entrants
  • Obtain formulation and manufacturing information
  • Drug patents in 130+ countries

Upgrade to enjoy subscriber-only features like email alerts and data export. See the Plans and Pricing

Serving leading biopharmaceutical companies globally:

Moodys
Fuji
Covington
Express Scripts
Healthtrust
Dow
Cipla
Accenture
AstraZeneca
Cerilliant

Generated: November 22, 2017

DrugPatentWatch Database Preview

Incyte Corp Company Profile

« Back to Dashboard

What is the competitive landscape for INCYTE CORP, and when can generic versions of INCYTE CORP drugs launch?

INCYTE CORP has one approved drug.

There are seven US patents protecting INCYTE CORP drugs on INCYTE CORP drugs in the past three years.

There are one hundred and fifty-one patent family members on INCYTE CORP drugs in forty-one countries and twenty supplementary protection certificates in thirteen countries.

Summary for Incyte Corp

International Patents:151
US Patents:7
Tradenames:1
Ingredients:1
NDAs:1
Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Exclusivity Expiration
Incyte Corp
JAKAFI
ruxolitinib phosphate
TABLET;ORAL202192-001Nov 16, 2011RXYesNo► Subscribe► SubscribeY ► Subscribe
Incyte Corp
JAKAFI
ruxolitinib phosphate
TABLET;ORAL202192-004Nov 16, 2011RXYesNo► Subscribe► SubscribeYY ► Subscribe
Incyte Corp
JAKAFI
ruxolitinib phosphate
TABLET;ORAL202192-003Nov 16, 2011RXYesNo► Subscribe► Subscribe► Subscribe
Incyte Corp
JAKAFI
ruxolitinib phosphate
TABLET;ORAL202192-004Nov 16, 2011RXYesNo► Subscribe► Subscribe► Subscribe
Incyte Corp
JAKAFI
ruxolitinib phosphate
TABLET;ORAL202192-001Nov 16, 2011RXYesNo► Subscribe► SubscribeYY ► Subscribe
Incyte Corp
JAKAFI
ruxolitinib phosphate
TABLET;ORAL202192-004Nov 16, 2011RXYesNo► Subscribe► Subscribe ► Subscribe
Incyte Corp
JAKAFI
ruxolitinib phosphate
TABLET;ORAL202192-005Nov 16, 2011RXYesYes► Subscribe► SubscribeYY ► Subscribe
Incyte Corp
JAKAFI
ruxolitinib phosphate
TABLET;ORAL202192-001Nov 16, 2011RXYesNo► Subscribe► Subscribe ► Subscribe
Incyte Corp
JAKAFI
ruxolitinib phosphate
TABLET;ORAL202192-001Nov 16, 2011RXYesNo► Subscribe► SubscribeYY ► Subscribe
Incyte Corp
JAKAFI
ruxolitinib phosphate
TABLET;ORAL202192-005Nov 16, 2011RXYesYes► Subscribe► Subscribe ► Subscribe
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

Paragraph IV activity for INCYTE CORP drugs

Drugname Dosage Strength Tradename Submissiondate
ruxolitinib
Tablets5 mg, 10 mg, 15 mg, 20 mg, and 25 mg
JAKAFI
12/17/2015

Non-Orange Book Patents for Incyte Corp

For Orange Book-listed patents (shown in the main table above) generic applications must certify that the listed patents are expired, invalid, or will not be infringed by generic entry.

The non-Orange Book patents listed below do not require formal certifications, so they do not automatically impede generic entry. Instead, they represent potential opportunities for branded firms to block generic entry through patent infringment challenges.

Patent No. Title Estimated Patent Expiration
8,530,485Heteroaryl substituted pyrrolo[2,3-b]pyridines and pyrrolo[2,3-b]pyrimidines as Janus kinase inhibitors► Subscribe
8,946,245Heteroaryl substituted pyrrolo[2,3-b]pyridines and pyrrolo[2,3-b]pyrimidines as Janus kinase inhibitors► Subscribe
9,206,187Heteroaryl substituted pyrrolo[2,3-B] pyridines and pyrrolo[2,3-B] pyrimidines as Janus kinase► Subscribe
9,376,439Salts of the janus kinase inhibitor (R)-3(4-(7H-pyrrolo[2,3-d]pyrimidin-4-yl)-1H-pyrazol-1-yl)-3-cyclopentylp- ropanenitrile► Subscribe
8,933,086Heteroaryl substituted pyrrolo[2,3-B]pyridines and pyrrolo[2,3-B]pyrimidines as Janus kinase inhibitors► Subscribe
8,541,425Heteroaryl substituted pyrrolo[2,3-b]pyridines and pyrrolo[2,3-b]pyrimidines as Janus kinase inhibitors► Subscribe
This preview shows a limited data set
Subscribe for full access, or try a Trial

The estimated expiration dates shown above are derived by simply adding 20 years to the priority date.
Because of the complexity of determining patent expiration dates it is advisable to have patent counsel verify freedom to operate.

Export unavailable in trial.
Subscribe for complete access.

International Patent Family for Incyte Corp Drugs

Country Document Number Estimated Expiration
Hong Kong1198652► Subscribe
SloveniaEP2474545► Subscribe
Costa Rica11151► Subscribe
Cyprus1115145► Subscribe
Taiwan201522344► Subscribe
SloveniaEP2455382► Subscribe
South Korea101391900► Subscribe
Singapore10201509887U► Subscribe
China103214483► Subscribe
European Patent Office2474545► Subscribe
This preview shows a limited data set
Subscribe for full access, or try a Trial

The estimated expiration dates shown above are derived by simply adding 20 years to the priority date.
Due to the complexity of determining patent expirations even in a single country, compounded by the diversity of global patent laws, it is advisable to have patent counsel verify freedom to operate.

Export unavailable in trial.
Subscribe for complete access.

Supplementary Protection Certificates for Incyte Corp Drugs

Supplementary Protection Certificate SPC Country SPC Expiration SPC Description
5 1-2013Slovakia► SubscribeFORMER OWNER: INCYTE CORPORATION, WILMINGTON, DE, US;
C0007France► SubscribePRODUCT NAME: RUXOLITINIB OU L'UN DE SES SELS PHARMACEUTIQUEMENT ACCEPTABLES; REGISTRATION NO/DATE: EU/1/12/773/001-003 20120823
137Luxembourg► SubscribePRODUCT NAME: RUXOLITINIB,OU UN DE SES SELS PHARMACEUTIQUEMENT ACCEPTABLES
13/004Ireland► SubscribePRODUCT NAME: RUXOLITINIB, OR A PHARMACEUTICALLY ACCEPTABLE SALT THREOF; REGISTRATION NO/DATE: EU/1/12/773/001-003 20120823
2013002Lithuania► Subscribe
2017 00018Denmark► SubscribePRODUCT NAME: RUXOLITINIB ELLER ET FARMACEUTISK ACCEPTABELT SALT DERAF, HERUNDER RUXOLITINIB FOSFAT; REG. NO/DATE: C(2015)1740/EU/1/12/773/001-016 20150313
2013 00005Denmark► Subscribe
0870Netherlands► SubscribePRODUCT NAME: RUXOLITINIB OF EEN FARMACEUTISCH AANVAARDBAAR ZOUT DAARVAN; REGISTRATION NO/DATE: EU/1/12/773/001-016 20150313
1966202/01Switzerland► SubscribeFORMER OWNER: INCYTE CORPORATION, US
0130003 00072Estonia► SubscribePRODUCT NAME: RUKSOLITINIIB;REG NO/DATE: K(2012)6018 LOPLIK 23.08.2012
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

Similar Applicant Names

Individual applicants are sometimes listed under multiple names.
Here is a list of applicants with similar names.

« Back to Dashboard

For more information try a trial or see the database preview and plans and pricing

Serving leading biopharmaceutical companies globally:

Accenture
Fuji
Julphar
Dow
Baxter
US Department of Justice
Johnson and Johnson
Boehringer Ingelheim
Farmers Insurance
McKinsey

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.

Copyright 2002-2017 thinkBiotech LLC
ISSN: 2162-2639

Secure SSL Encrypted
Privacy and Cookies
Terms & Conditions

Follow DrugPatentWatch:



Google
Twitter
Google Plus
botpot